Market Overview

CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

Share:
CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup
  • CombiMatrix Corp (NASDAQ: CBMX): Granted approval for pre-implantation genetic screening and conditional approval from NYS Department of Health.
  • CytRx Corporation (NASDAQ: CYTR): Announced Aldoxorubicin achieved primary endpoint, stating, “Statistically significant improvement in progression-free survival in patients with Liposarcoma." The company expects to submit an NDA with the FDA for Aldoxorubicin as treatment for patients with relapsed or refractory STS in 2017.
  • Dimension Therapeutics Inc (NASDAQ: DMTX) Received positive opinion for DTX401 for European orphan drug designation.
  • KemPharm Inc (NASDAQ: KMPH): Received FDA clearance to initiate KP201/IR trial.
  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA): Announced Phase III for M923 met primary endpoint and all secondary endpoints.
  • Novan Inc (NASDAQ: NOVN): Announced Phase II trial achieved significant results.
  • Vascular Biogenics Ltd (NASDAQ: VBLT): Announced VB-111 met primary endpoint, stating, "[It] shows evidence of overall survival rate."
  • All data compiled using Benzinga Pro

    Posted-In: Biotech News Health Care Movers & Shakers FDA Movers Tech Trading Ideas

     

    Related Articles (CBMX + CYTR)

    View Comments and Join the Discussion!

    Partner Center